Brian Smith, MD
Gastroenterology · Winston Salem, NCNPI 1093862898
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,963 of the $5,733 with a category attached, or 69.1%. 37 manufacturers reported payments, led by AbbVie at 44.3% of the total. Reporting peaked in 2020 at $1,924 and has fallen 57.9% since, to $810 in 2025.
Across 234 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$498
- Takeda Pharmaceuticals U.S.A., Inc.$358
- Johnson & Johnson$251
- Pfizer$247
- Fujifilm Healthcare Americas Corporation$241
- plus $2K from 31 others
Across 195 payments — averaging $3391.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$315K
- Pfizer$149K
- Intercept Pharmaceuticals, Inc.$72K
- Ironwood Pharmaceuticals, Inc$71K
- Janssen Research & Development, LLC$34K
- Novartis$17K
- plus $4K from 1 others
What the payments were for
- Consulting fees$1,50026%
- Food & beverage$3,96369%
- Education$301%
- Gifts$1503%
- Other$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $2,539 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $498 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $358 |
| Johnson & Johnson | 12 | $251 |
| Pfizer | 17 | $247 |
| Fujifilm Healthcare Americas Corporation | 6 | $241 |
| Gilead | 12 | $202 |
| Intercept Pharmaceuticals, Inc. | 11 | $177 |
| QOL Medical, LLC | 10 | $141 |
| Bristol Myers Squibb | 7 | $115 |
| Madrigal Pharmaceuticals | 3 | $96 |
| Daiichi Sankyo Inc. | 3 | $75 |
| Ironwood Pharmaceuticals, Inc | 5 | $74 |
| Sanofi | 3 | $70 |
| Merck | 4 | $61 |
| Redhill Biopharma Inc. | 1 | $53 |
| Ferring Pharmaceuticals Inc. | 3 | $52 |
| Ipsen Biopharmaceuticals, Inc | 2 | $48 |
| UCB, Inc. | 3 | $46 |
| Lilly USA, LLC | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $31 |
| Shire North American Group Inc | 2 | $30 |
| Intra-sana Laboratories | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Organon | 1 | $28 |
| Amgen | 1 | $24 |
| Medtronic | 1 | $23 |
| Celltrion USA Inc. | 1 | $22 |
| AstraZeneca | 1 | $20 |
| Mylan Institutional Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| Shionogi Inc | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
| CSL Behring | 1 | $15 |
| Sandoz | 1 | $13 |
| Micro-tech Endoscopy USA, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$1,500
- ESD - Core Endoscopy$148
How this compares
$5,733 in reported general payments places this provider in the 70th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 15 | $213,463 |
| XifaxanRifaximin | 49 | $150,798 |
| LinzessLinaclotide | 150 | $127,673 |
| ZenpepLipase/Protease/Amylase | 11 | $19,280 |
| Dexlansoprazole DrDexlansoprazole | 15 | $5,814 |
| Ursodiol | 24 | $4,789 |
| Pantoprazole Sodium | 460 | $4,723 |
| Budesonide DrBudesonide | 38 | $4,116 |
| Dicyclomine Hcl | 155 | $4,092 |
| Mesalamine | 25 | $3,576 |
| Ondansetron OdtOndansetron | 111 | $3,199 |
| Omeprazole | 138 | $2,621 |
| Mercaptopurine | 32 | $2,332 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 13 | $2,135 |
| Budesonide EcBudesonide | 21 | $1,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $177 | $213,46315 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $498 | $150,79849 claims |
| AbbVieLinzess | $2,539 | $127,673150 claims |
| Aimmune Therapeutics, Inc.Zenpep | $31 | $19,28011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Winston Salem
- Andrew StormWinston Salem$426K
- Kenneth KochWinston Salem$74K
- Herbert BonkovskyWinston Salem$57K
- Girish MishraWinston Salem$56K
- Richard BloomfeldWinston Salem$27K
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.